2024
Adjunctive N-Acetylcysteine and Lung Function in Pulmonary Tuberculosis.
Wallis R, Sabi I, Lalashowi J, Bakuli A, Mapamba D, Olomi W, Siyame E, Ngaraguza B, Chimbe O, Charalambous S, Rachow A, Ivanova O, Zurba L, Myombe B, Kunambi R, Hoelscher M, Ntinginya N, Churchyard G. Adjunctive N-Acetylcysteine and Lung Function in Pulmonary Tuberculosis. NEJM Evidence 2024, 3: evidoa2300332. PMID: 39189858, DOI: 10.1056/evidoa2300332.Peer-Reviewed Original ResearchConceptsWhole blood glutathione levelsLung functionN-acetylcysteinePulmonary tuberculosisCulture conversionSecondary outcomesGlutathione levelsEffect of N-acetylcysteineTuberculosis treatment outcomesOutcome of lung functionOral N-acetylcysteineRecovery of lung functionAdjunctive N-acetylcysteineAssociated with improved recoveryN-acetylcysteine treatmentPermanent lung injuryFar-advanced tuberculosisSputum cultureStandard therapyNAC administrationAdverse eventsLung injuryGlobal health concernCohort studyClinical evaluation
2022
Machine learning prediction of exposure to acrylamide based on modelling of association between dietary exposure and internal biomarkers
Wan X, Zhang Y, Gao S, Shen X, Jia W, Pan X, Zhuang P, Jiao J, Zhang Y. Machine learning prediction of exposure to acrylamide based on modelling of association between dietary exposure and internal biomarkers. Food And Chemical Toxicology 2022, 170: 113498. PMID: 36328216, DOI: 10.1016/j.fct.2022.113498.Peer-Reviewed Original ResearchMeSH KeywordsAcetylcysteineAcrylamideAgedBiomarkersDietary ExposureHumansMachine LearningMiddle AgedConceptsDietary exposureElderly populationInternal exposureTotal energy intakeDietary acrylamide exposureChinese elderly populationAverage dietary intakeN-acetylExposure assessmentRegression modelsUrinary biomarkersDietary intakeUrinary contentAcrylamide exposureChinese cohortPhysical activityAccurate exposure assessmentEnergy intakeElderly participantsPotential health risksL-cysteineImportant covariatesLinear regression modelsHealth risksExposureOxidative stress induces inflammation of lens cells and triggers immune surveillance of ocular tissues
Thompson B, Davidson EA, Chen Y, Orlicky DJ, Thompson DC, Vasiliou V. Oxidative stress induces inflammation of lens cells and triggers immune surveillance of ocular tissues. Chemico-Biological Interactions 2022, 355: 109804. PMID: 35123994, PMCID: PMC9136680, DOI: 10.1016/j.cbi.2022.109804.Peer-Reviewed Original ResearchMeSH KeywordsAcetylcysteineAnimalsButhionine SulfoximineCell LineChemokine CCL7CytokinesDown-RegulationEpithelial CellsEpithelial-Mesenchymal TransitionEyeGlutamate-Cysteine LigaseImmunity, InnateLens, CrystallineLeukocytesMiceMice, Inbred C57BLMice, KnockoutOxidative StressReactive Oxygen SpeciesUp-RegulationConceptsPosterior capsule opacificationCytokine expressionKO miceImmune surveillanceOxidative stressLens epithelial cellsOcular structuresLens cellsDevelopment of PCOEpithelial cellsInnate immune cellsExpression of cytokinesEx vivo inductionOcular surface tissuesExpression of markersImmune response genesCON miceControl miceCapsule opacificationImmune cellsPostnatal dayΑ-SMAMouse modelOcular tissuesVivo inductionAssociations of 3-monochloropropane-1,2-diol and glycidol with prevalence of metabolic syndrome: Findings from Lanxi Nutrition and Safety Study
Wan X, Jia W, Zhuang P, Wu F, Zhang Y, Shen X, Liu X, Zheng W, Jiao J, Zhang Y. Associations of 3-monochloropropane-1,2-diol and glycidol with prevalence of metabolic syndrome: Findings from Lanxi Nutrition and Safety Study. Environmental Research 2022, 209: 112746. PMID: 35063427, DOI: 10.1016/j.envres.2022.112746.Peer-Reviewed Original ResearchConceptsMetS prevalenceMetS casesRisk factorsAdult Treatment Panel III criteriaNational Cholesterol Education ProgramCholesterol Education ProgramBehavioral risk factorsPotential risk factorsUrinary creatinine contentPositive associationChinese elderly peoplePoisson regression modelsHypertriglyceridemia prevalencePrevalent MetSMetabolic syndromeUrinary biomarkersLowest quartileHigh prevalenceRelative riskElderly populationMercapturic acidsDietary exposurePrevalenceSafety studiesStrong positive association
2020
Pharmacological and behavioral treatment for trichotillomania: An updated systematic review with meta‐analysis
Farhat LC, Olfson E, Nasir M, Levine JLS, Li F, Miguel EC, Bloch MH. Pharmacological and behavioral treatment for trichotillomania: An updated systematic review with meta‐analysis. Depression And Anxiety 2020, 37: 715-727. PMID: 32390221, DOI: 10.1002/da.23028.Peer-Reviewed Original ResearchMeSH KeywordsAcetylcysteineBehavior TherapyClomipramineHumansSelective Serotonin Reuptake InhibitorsTrichotillomaniaConceptsClinical trialsSingle randomized clinical trialTTM symptomsFirst-line medicationRandomized clinical trialsStrong evidence baseLarge treatment effectsHair pulling disorderEffective medicationsAvailable agentsPharmacological agentsAdditional trialsDrug AdministrationPsychiatric conditionsSystematic reviewN-acetylcysteineBehavioral treatmentBehavioral therapyEvidence baseTrichotillomaniaTrialsRelative efficacyTreatment effectsMedicationsSymptoms
2019
N-Acetylcysteine for Pediatric Obsessive-Compulsive Disorder: A Small Pilot Study
Li F, Welling MC, Johnson JA, Coughlin C, Mulqueen J, Jakubovski E, Coury S, Landeros-Weisenberger A, Bloch MH. N-Acetylcysteine for Pediatric Obsessive-Compulsive Disorder: A Small Pilot Study. Journal Of Child And Adolescent Psychopharmacology 2019, 30: 32-37. PMID: 31800306, PMCID: PMC7133418, DOI: 10.1089/cap.2019.0041.Peer-Reviewed Original ResearchConceptsCY-BOCS total scoreN-acetylcysteineYale-Brown ObsessiveTotal scorePlacebo groupNAC groupStudy populationBenefit of NACPlacebo-controlled clinical trialSymptom severityEffect of NACMild adverse eventsOCD symptom severityLarger study populationPediatric obsessive-compulsive disorderSmall pilot studyChildren's Yale-Brown ObsessiveStudy medicationAdverse eventsPrimary outcomeGlutamate dysfunctionObsessive-compulsive disorderWeek 12Future trialsNAC treatmentFABP7 Protects Astrocytes Against ROS Toxicity via Lipid Droplet Formation
Islam A, Kagawa Y, Miyazaki H, Shil SK, Umaru BA, Yasumoto Y, Yamamoto Y, Owada Y. FABP7 Protects Astrocytes Against ROS Toxicity via Lipid Droplet Formation. Molecular Neurobiology 2019, 56: 5763-5779. PMID: 30680690, DOI: 10.1007/s12035-019-1489-2.Peer-Reviewed Original ResearchConceptsMitogen-activated protein kinaseROS toxicityLipid droplet formationLD accumulationPeroxiredoxin 1Stress-activated protein kinase/c-Jun N-terminal kinaseProtein kinase/c-Jun N-terminal kinaseP38 mitogen-activated protein kinaseC-Jun N-terminal kinaseReactive oxygen species stressRole of FABP7ROS inductionU87 human glioma cell lineN-terminal kinaseOxygen species stressActivation of apoptosisFABP7 overexpressionProtein bindsProtein kinaseLD formationLong-chain fatty acidsROS stressHuman glioma cell linesLipid dynamicsWild-type astrocytes
2017
Randomized, Double-Blind, Placebo-Controlled Trial of N-Acetylcysteine Augmentation for Treatment-Resistant Obsessive-Compulsive Disorder.
Costa DLC, Diniz JB, Requena G, Joaquim MA, Pittenger C, Bloch MH, Miguel EC, Shavitt RG. Randomized, Double-Blind, Placebo-Controlled Trial of N-Acetylcysteine Augmentation for Treatment-Resistant Obsessive-Compulsive Disorder. The Journal Of Clinical Psychiatry 2017, 78: e766-e773. PMID: 28617566, DOI: 10.4088/jcp.16m11101.Peer-Reviewed Original ResearchMeSH KeywordsAcetylcysteineAdolescentAdultAgedAnxiety DisordersComorbidityDepressive DisorderDouble-Blind MethodDrug ResistanceDrug Therapy, CombinationFemaleHumansMaleMiddle AgedObsessive-Compulsive DisorderPsychiatric Status Rating ScalesPsychometricsSelective Serotonin Reuptake InhibitorsYoung AdultConceptsTreatment-resistant obsessive-compulsive disorderObsessive-compulsive disorderY-BOCS scoresN-acetylcysteineNAC groupYale-Brown Obsessive Compulsive Scale scoresTreatment-resistant OCD patientsBaseline Y-BOCS scoresTreatment-Resistant ObsessivePrimary outcome measureAnxiety symptomsDSM-IV criteriaSymptom dimensionsCompulsive Scale scoresSpecific OCD symptom dimensionsOCD symptom dimensionsAntioxidant medicationsAbdominal painPlacebo groupGlutamate modulatorsSecondary outcomesTertiary hospitalOutpatient clinicSeverity scoreWeek 16Novel Role of the Mitochondrial Protein Fus1 in Protection from Premature Hearing Loss via Regulation of Oxidative Stress and Nutrient and Energy Sensing Pathways in the Inner Ear
Tan WJ, Song L, Graham M, Schettino A, Navaratnam D, Yarbrough WG, Santos-Sacchi J, Ivanova AV. Novel Role of the Mitochondrial Protein Fus1 in Protection from Premature Hearing Loss via Regulation of Oxidative Stress and Nutrient and Energy Sensing Pathways in the Inner Ear. Antioxidants & Redox Signaling 2017, 27: 489-509. PMID: 28135838, PMCID: PMC5564041, DOI: 10.1089/ars.2016.6851.Peer-Reviewed Original ResearchMeSH KeywordsAcetylcysteineAnimalsAntioxidantsDisease Models, AnimalEar, InnerEvoked Potentials, Auditory, Brain StemGene Knockout TechniquesHearing LossHumansMiceMicroscopy, Electron, TransmissionMitochondriaOxidative StressProto-Oncogene Proteins c-aktPTEN PhosphohydrolaseSignal TransductionSpiral GanglionTOR Serine-Threonine KinasesTumor Suppressor ProteinsConceptsAge-related hearing lossAuditory brainstem responseHearing lossKO miceEndocochlear potentialOxidative stressMitochondrial dysfunctionMitochondrial dysfunction/oxidative stressEnergy sensing pathwaysNovel therapeutic strategiesMolecular mechanismsPremature hearing lossCochlear stria vascularisMajor hearing lossChronic mitochondrial dysfunctionMetabolic etiologyWorldwide epidemicBrainstem responseClinical trialsVascular pathologyTherapeutic strategiesPathological alterationsABR parametersAO treatmentStria vascularis
2016
N-Acetylcysteine in the Treatment of Pediatric Tourette Syndrome: Randomized, Double-Blind, Placebo-Controlled Add-On Trial
Bloch MH, Panza KE, Yaffa A, Alvarenga PG, Jakubovski E, Mulqueen JM, Landeros-Weisenberger A, Leckman JF. N-Acetylcysteine in the Treatment of Pediatric Tourette Syndrome: Randomized, Double-Blind, Placebo-Controlled Add-On Trial. Journal Of Child And Adolescent Psychopharmacology 2016, 26: 327-334. PMID: 27027204, PMCID: PMC6445198, DOI: 10.1089/cap.2015.0109.Peer-Reviewed Original ResearchConceptsBenefit of NACEfficacy of NACYale Global Tic Severity ScaleAttention-deficit/hyperactivity disorderObsessive-compulsive disorderTourette syndromeN-acetylcysteineObsessive-compulsive spectrum disordersSide effectsRecent placebo-controlled trialPediatric Tourette syndromePlacebo-controlled trialCurrent pharmacological treatmentsTreatment of ticsTotal tic scoreSeverity of ticsSubstantial side effectsTic Severity ScaleYears of ageMinimal side effectsPediatric TSPrimary outcomeSecondary outcomesGlutamatergic systemPharmacological treatment
2015
In vitro cleavage of diisocyanate-glutathione conjugates by human gamma-glutamyl transpeptidase-1
Wisnewski AV, Liu J, Nassar AF. In vitro cleavage of diisocyanate-glutathione conjugates by human gamma-glutamyl transpeptidase-1. Xenobiotica 2015, 46: 726-732. PMID: 26678254, PMCID: PMC4848134, DOI: 10.3109/00498254.2015.1118576.Peer-Reviewed Original ResearchN-acetylcysteine decreased nicotine reward-like properties and withdrawal in mice
Bowers M, Jackson A, Maldoon P, Damaj M. N-acetylcysteine decreased nicotine reward-like properties and withdrawal in mice. Psychopharmacology 2015, 233: 995-1003. PMID: 26676982, PMCID: PMC4819399, DOI: 10.1007/s00213-015-4179-4.Peer-Reviewed Original ResearchConceptsAnxiety-like behaviorN-acetylcysteineContinuous nicotineNicotine place conditioningSaline-treated miceNicotine-treated miceMale ICR miceSomatic withdrawal signsHigh clinical utilityPlace aversion paradigmPlace preference paradigmReward-like propertiesN-acetylcysteine pretreatmentSpontaneous withdrawalExtrasynaptic glutamateWithdrawal signsICR miceNicotine rewardSmoking ratesSomatic signsClinical utilityNicotine dependenceFood CPPNicotine CPPObjectivesThe aimEffects of ROS-relative NF-κB signaling on high glucose-induced TLR4 and MCP-1 expression in podocyte injury
Wei M, Li Z, Xiao L, Yang Z. Effects of ROS-relative NF-κB signaling on high glucose-induced TLR4 and MCP-1 expression in podocyte injury. Molecular Immunology 2015, 68: 261-271. PMID: 26364141, DOI: 10.1016/j.molimm.2015.09.002.Peer-Reviewed Original ResearchConceptsToll-like receptor 4Diabetic nephropathyMCP-1 expressionNF-κB inhibitionMCP-1High glucoseReactive oxygen speciesNF-κBSuppression of TLR4NF-κB-dependent signalingChemoattractant protein-1Effects of HGPotential therapeutic targetNF-κB signalingCell viabilityIntracellular reactive oxygen speciesEffects of ROSWestern blot analysisTLR-4Receptor 4Intracellular ROS generationPodocyte injuryPodocyte damageProtective effectCell injuryLONG‐TERM OUTCOME IN PEDIATRIC TRICHOTILLOMANIA
Schumer MC, Panza KE, Mulqueen JM, Jakubovski E, Bloch MH. LONG‐TERM OUTCOME IN PEDIATRIC TRICHOTILLOMANIA. Depression And Anxiety 2015, 32: 737-743. PMID: 26139231, PMCID: PMC4591183, DOI: 10.1002/da.22390.Peer-Reviewed Original ResearchConceptsPoor long-term prognosisLong-term prognosisLong-term outcomesN-acetylcysteineDepressive symptomsPediatric trichotillomaniaTrichotillomania symptomsOlder ageAdequate symptom reliefPlacebo-controlled trialAnxiety symptomsPredictors of outcomePrevious cross-sectional studiesRisk of depressionCross-sectional studyPrimary outcomeSymptom reliefAcute phaseClinical assessmentTreatment utilizationBaseline evaluationSecondary measuresBaseline assessmentSymptomsBehavioral treatment
2014
Long-term treatment with oral N-acetylcysteine: Affects lung function but not sputum inflammation in cystic fibrosis subjects. A phase II randomized placebo-controlled trial
Conrad C, Lymp J, Thompson V, Dunn C, Davies Z, Chatfield B, Nichols D, Clancy J, Vender R, Egan M, Quittell L, Michelson P, Antony V, Spahr J, Rubenstein R, Moss R, Herzenberg L, Goss C, Tirouvanziam R. Long-term treatment with oral N-acetylcysteine: Affects lung function but not sputum inflammation in cystic fibrosis subjects. A phase II randomized placebo-controlled trial. Journal Of Cystic Fibrosis 2014, 14: 219-227. PMID: 25228446, DOI: 10.1016/j.jcf.2014.08.008.Peer-Reviewed Original ResearchConceptsOral N-acetylcysteineLung functionN-acetylcysteineHNE activityHuman neutrophil elastase (HNE) activityDouble-blind proofPlacebo-controlled trialNeutrophil elastase activityPotential of NACLong-term treatmentLung function measuresCystic fibrosis subjectsPlacebo recipientsNeutrophilic inflammationPlacebo groupPulmonary hypertensionClinical outcomesNAC groupCF subjectsCF airwaysSystemic glutathioneNAC recipientsFunction measuresElastase activityInflammation
2013
Studies of the metabotropic glutamate receptor 5 radioligand [11C]ABP688 with N‐acetylcysteine challenge in rhesus monkeys
Sandiego CM, Nabulsi N, Lin S, Labaree D, Najafzadeh S, Huang Y, Cosgrove K, Carson RE. Studies of the metabotropic glutamate receptor 5 radioligand [11C]ABP688 with N‐acetylcysteine challenge in rhesus monkeys. Synapse 2013, 67: 489-501. PMID: 23424090, PMCID: PMC3710146, DOI: 10.1002/syn.21656.Peer-Reviewed Original ResearchConceptsN-acetylcysteineRhesus monkeysCerebellum gray matterMetabotropic glutamate receptor 5N-acetylcysteine challengeBaboon studiesGlutamate receptor 5Non-displaceable binding potentialHigh intersubject variabilityReference regionRecent pilot studySignificant global decreaseGlutamate transmissionNAC doseEndogenous glutamatePsychiatric illnessReceptor 5Gray matterAllosteric antagonistsPilot studyReceptor bindingIntersubject variabilitySame dayDoseMonkeysN-Acetylcysteine in the Treatment of Pediatric Trichotillomania: A Randomized, Double-Blind, Placebo-Controlled Add-On Trial
Bloch MH, Panza KE, Grant JE, Pittenger C, Leckman JF. N-Acetylcysteine in the Treatment of Pediatric Trichotillomania: A Randomized, Double-Blind, Placebo-Controlled Add-On Trial. Journal Of The American Academy Of Child & Adolescent Psychiatry 2013, 52: 231-240. PMID: 23452680, PMCID: PMC3745012, DOI: 10.1016/j.jaac.2012.12.020.Peer-Reviewed Original ResearchConceptsN-acetylcysteinePharmacological interventionsPediatric trichotillomaniaBenefit of NACBehavioral therapySecondary outcome measuresTreatment of childrenClinician-rated improvementMassachusetts General HospitalTreat populationPlacebo groupPrimary outcomeNAC groupGeneral HospitalOutcome measuresTreatment respondersSecondary measuresPlaceboTreatment assignmentTrichotillomaniaLinear mixed modelsTrialsSignificant differencesChildrenTherapyAmelioration of Acute Sequelae of Blast Induced Mild Traumatic Brain Injury by N-Acetyl Cysteine: A Double-Blind, Placebo Controlled Study
Hoffer ME, Balaban C, Slade MD, Tsao JW, Hoffer B. Amelioration of Acute Sequelae of Blast Induced Mild Traumatic Brain Injury by N-Acetyl Cysteine: A Double-Blind, Placebo Controlled Study. PLOS ONE 2013, 8: e54163. PMID: 23372680, PMCID: PMC3553161, DOI: 10.1371/journal.pone.0054163.Peer-Reviewed Original ResearchConceptsMild traumatic brain injuryN-acetyl cysteineTraumatic brain injuryBrain injuryOutcome measuresPlacebo-controlled studyPlacebo Controlled StudyLong-term outcomesMain outcome measuresReported side effectsService membersActive duty service membersU.S. service membersAcute sequelaeSymptom resolutionTerm outcomesControlled StudyNAC treatmentSleep disturbancesHearing lossNeurocognitive dysfunctionBaseline evaluationCivilian mild traumatic brain injuryBlast exposurePlacebo
2012
Use of N‐acetylcysteine during liver procurement: A prospective randomized controlled study
D'Amico F, Vitale A, Piovan D, Bertacco A, Morales R, Frigo A, Bassi D, Bonsignore P, Gringeri E, Valmasoni M, Garbo G, Lodo E, D'Amico FE, Scopelliti M, Carraro A, Gambato M, Brolese A, Zanus G, Neri D, Cillo U. Use of N‐acetylcysteine during liver procurement: A prospective randomized controlled study. Liver Transplantation 2012, 19: 135-144. PMID: 22859317, DOI: 10.1002/lt.23527.Peer-Reviewed Original ResearchMeSH KeywordsAcetylcysteineAdolescentAdultAgedAntioxidantsChi-Square DistributionFemaleGraft SurvivalHumansInfusions, IntravenousItalyKaplan-Meier EstimateLiver TransplantationMaleMiddle AgedPortal VeinPrimary Graft DysfunctionProportional Hazards ModelsProspective StudiesSingle-Blind MethodTime FactorsTissue and Organ HarvestingTreatment OutcomeYoung AdultConceptsGraft survivalLiver transplantationNAC groupLiver procurementN-acetylcysteineControl groupSuboptimal graftsEffect of NACNAC protocolIschemia/reperfusion damageFirst liver transplantationEarly graft functionGraft survival ratesChronic liver diseaseSingle-blinded procedureGraft functionLT outcomesPostoperative complicationsPrimary endpointCox analysisNAC infusionRandomized studyLiver diseaseAdult candidatesPrimary dysfunction
2011
Inhibition of Pyruvate Kinase M2 by Reactive Oxygen Species Contributes to Cellular Antioxidant Responses
Anastasiou D, Poulogiannis G, Asara J, Boxer M, Jiang J, Shen M, Bellinger G, Sasaki A, Locasale J, Auld D, Thomas C, Vander Heiden M, Cantley L. Inhibition of Pyruvate Kinase M2 by Reactive Oxygen Species Contributes to Cellular Antioxidant Responses. Science 2011, 334: 1278-1283. PMID: 22052977, PMCID: PMC3471535, DOI: 10.1126/science.1211485.Peer-Reviewed Original ResearchMeSH KeywordsAcetylcysteineAmino Acid SubstitutionAnimalsAntioxidantsCell LineCell Line, TumorCell SurvivalCysteineDiamideEnzyme ActivatorsGlucoseGlutathioneHumansMiceMice, NudeMutant ProteinsNeoplasm TransplantationNeoplasms, ExperimentalOxidation-ReductionOxidative StressPentose Phosphate PathwayProtein SubunitsPyruvate KinaseReactive Oxygen SpeciesTransplantation, HeterologousConceptsPyruvate kinase M2Lung cancer cellsCancer cellsKinase M2Human lung cancer cellsReactive oxygen species contributesInhibition of PKM2Intracellular reactive oxygen species (ROS) concentrationCancer cell survivalCellular antioxidant responseGlycolytic enzyme pyruvate kinase M2Acute increaseXenograft modelReactive oxygen species concentrationMetabolic changesOxidative stressTumor formationGlucose fluxCell survivalIntracellular concentrationAntioxidant responseInhibitionCellsOxygen species concentrationROS
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply